No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Celltrion’s Biosimilar Aflibercept Sixth Approved in US
On 10 October 2025, Celltrion announced that the FDA has approved Eydenzelt® (CT-P42), biosimilar to Regeneron/Bayer’s Eylea (aflibercept 2mg), for treating nAMD, macular oedema following retinal vein occlusion, diabetic macular oedema and diabetic retinopathy.